The von Hippel-Lindau tumour suppressor: A multi-faceted inhibitor of tumourigenesis

Trends in Molecular Medicine

Volumn 10, Issue 9, 2004, Pages 466-472

  Barry, Robert E ^a   Krek, Wilhelm ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; PROTEIN SUBUNIT; VON HIPPEL LINDAU PROTEIN;

CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL ACTIVITY; CELL DEATH; CELL MIGRATION; CELL POLARITY; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; GENE EXPRESSION; GENOTYPE; HUMAN; METASTASIS; MICROTUBULE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VON HIPPEL LINDAU DISEASE;

DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 4444313558     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.07.008     Document Type: Review

References (66)

1. R.R. Lonser von Hippel-Lindau disease Lancet 361 2003 2059 2067
2. A.G. Knudson Jr Mutation and cancer: statistical study of retinoblastoma Proc. Natl. Acad. Sci. U. S. A. 68 1971 820 823
3. C. Stolle Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene Hum. Mutat. 12 1998 417 423
4. E.R. Maher, and W.G. Kaelin Jr von Hippel-Lindau disease Medicine (Baltimore) 76 1997 381 391
5. B. Zbar Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan Hum. Mutat. 8 1996 348 357
6. C. Beroud Software and database for the analysis of mutations in the VHL gene Nucleic Acids Res. 26 1998 256 258
7. F.M. Richards Molecular pathology of von Hippel-Lindau disease and the VHL tumour suppressor gene Expert Rev. Mol. Med. 1 2001 1 27
8. J.K. McLaughlin, and L. Lipworth Epidemiologic aspects of renal cell cancer Semin. Oncol. 27 2000 115 123
9. F.M. Richards Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis Hum. Mol. Genet. 2 1993 879 882
10. O. Iliopoulos pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation Proc. Natl. Acad. Sci. U. S. A. 95 1998 11661 11666
11. F.M. Richards Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis Hum. Mol. Genet. 5 1996 639 644
12. A. Hergovich Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL Nat. Cell Biol. 5 2003 64 70
13. J.R. Gnarra Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice Proc. Natl. Acad. Sci. U. S. A. 94 1997 9102 9107
14. V.H. Haase Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor Proc. Natl. Acad. Sci. U. S. A. 98 2001 1583 1588
15. W. Ma Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene Cancer Res. 63 2003 5320 5328
16. E. Kleymenova Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice Carcinogenesis 25 2004 309 315
17. J. Lisztwan The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity Genes Dev. 13 1999 1822 1833
18. P.H. Maxwell The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 1999 271 275
19. G.L. Semenza HIF-1 and tumor progression: pathophysiology and therapeutics Trends Mol. Med. 8 Suppl. 4 2002 S62 S67
20. -/- tumors Mol. Cancer Res. 2 2004 89 95
21. K. Kondo Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth PLoS Biol. 1 2003 E83
22. F.A. Mack Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth Cancer Cell 3 2003 75 88
23. J.R. Gnarra Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proc. Natl. Acad. Sci. U. S. A. 93 1996 10589 10594
24. B. Gunawan Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis Cancer Res. 61 2001 7731 7738
25. -/- renal cell carcinoma cells J. Biol. Chem. 278 2003 44966 44974
26. B. Knebelmann Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor Cancer Res. 58 1998 226 231
27. -/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis Proc. Natl. Acad. Sci. U. S. A. 98 2001 1387 1392
28. W.G. Kaelin Jr Molecular basis of the VHL hereditary cancer syndrome Nat. Rev. Cancer 2 2002 673 682
29. P. Carmeliet Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Nature 394 1998 485 490
30. A.R. Schoenfeld The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis Oncogene 19 2000 5851 5857
31. P. Devarajan The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways J. Biol. Chem. 276 2001 40599 40605
32. C. Potter, and A.L. Harris Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target Cell Cycle 3 2004 164 167
33. T. Hellwig-Burgel Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1 Blood 94 1999 1561 1567
34. J.E. Albina HIF-1 expression in healing wounds: HIF-1α induction in primary inflammatory cells by TNF-α Am. J. Physiol. Cell Physiol. 281 2001 C1971 C1977
35. K.J. Tracey, and A. Cerami Tumor necrosis factor, other cytokines and disease Annu. Rev. Cell Biol. 9 1993 317 343
36. Y. Jung Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor κ B activation Biochem. J. 370 2003 1011 1017
37. M.C. Caldwell Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFα cytotoxicity Oncogene 21 2002 929 936
38. H. Qi, and M. Ohh The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-κB-dependent antiapoptotic pathway Cancer Res. 63 2003 7076 7080
39. H. Okuda Direct interaction of the β-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes Biochem. Biophys. Res. Commun. 263 1999 491 497
40. H. Okuda The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C J. Biol. Chem. 276 2001 43611 43617
41. S. Aznavoorian Molecular aspects of tumor cell invasion and metastasis Cancer 71 1993 1368 1383
42. E. Ruoslahti Fibronectin and its integrin receptors in cancer Adv. Cancer Res. 76 1999 1 20
43. F.G. Giancotti, and E. Ruoslahti Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells Cell 60 1990 849 859
44. M. Ohh The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol. Cell 1 1998 959 968
45. B. Lieubeau-Teillet von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids Cancer Res. 58 1998 4957 4962
46. M.A. Esteban-Barragan Role of the von Hippel-Lindau tumor suppressor gene in the formation of β1-integrin fibrillar adhesions Cancer Res. 62 2002 2929 2936
47. N.H. Stickle pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development Mol. Cell. Biol. 24 2004 3251 3261
48. W. Li Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation Mol. Cell. Biol. 18 1998 5888 5898
49. S. Etienne-Manneville, and A. Hall Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity Nature 421 2003 753 756
50. R. Fodde The APC gene in colorectal cancer Eur. J. Cancer 38 2002 867 871
51. S. Koochekpour The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells Mol. Cell. Biol. 19 1999 5902 5912
52. P. Staller Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 425 2003 307 311
53. M.A. Lafleur Metalloproteinases and their inhibitors in angiogenesis Expert Rev. Mol. Med. 5 2003 1 39
54. S. Pennacchietti Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
55. A. Muller Involvement of chemokine receptors in breast cancer metastasis Nature 410 2001 50 56
56. T. Schioppa Regulation of the chemokine receptor CXCR4 by hypoxia J. Exp. Med. 198 2003 1391 1402
57. I.R. Maddock A genetic register for von Hippel-Lindau disease J. Med. Genet. 33 1996 120 127
58. E.R. Maher Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma J. Med. Genet. 27 1990 311 314
59. S. Richard Haemangioblastoma of the central nervous system in von Hippel-Lindau disease J. Intern. Med. 243 1998 547 553
60. N. Masson Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation EMBO J. 20 2001 5197 5206
61. A.C. Epstein C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 2001 43 54
62. D. Lando Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch Science 295 2002 858 861
63. P.C. Mahon FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev. 15 2001 2675 2686
64. C.W. Pugh, and P.J. Ratcliffe Regulation of angiogenesis by hypoxia: role of the HIF system Nat. Med. 9 2003 677 684
65. J.W. Jeong Regulation and destabilization of HIF-1α by ARD1-mediated acetylation Cell 111 2002 709 720
66. M.K. Bae Jab1 interacts directly with HIF-1α and regulates its stability J. Biol. Chem. 277 2002 9 12